Clinical Trial

Recce Pharmaceuticals Doses All Patients in Phase II Trial of RECCE® 327 Topical Gel in Acute Bacterial Skin and Skin Structure Infections

Preliminary data indicates patients experienced either a complete cure or significant improvement in infection symptoms following treatment with R327GFull data…

11 months ago

Hepion Pharmaceuticals Announces $9.0 Million Public Offering

EDISON, N.J., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that has been…

11 months ago

Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema

CAMBRIDGE, Mass., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on…

11 months ago

Rakovina Therapeutics Comments on $500 Billion AI Infrastructure Investment and Its Implications for Healthcare Innovation

VANCOUVER, British Columbia, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company at the forefront…

11 months ago

Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy

Received supportive FDA feedback on key elements of the potential ELI-002 Phase 3 study design, including dose, schedule, patient population…

11 months ago

SeaStar Medical Activates 15th Site for its Adult Acute Kidney Injury Pivotal Trial

DENVER, Jan. 22, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary…

11 months ago

Clearside Biomedical Announces its Asia-Pacific Partner, Arctic Vision, Received Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and Singapore

- ARCATUS®, Branded as XIPERE® in the U.S., is the First Globally Approved Suprachoroidal Therapy - - Continued Global Expansion…

11 months ago

Kamada Announces a $25 Million 3-Year Contract for Supply of KAMRAB® and VARIZIG® in Latin America

REHOVOT, Israel and HOBOKEN, N.J., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical…

11 months ago

Nurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer

Mr. Northcott brings over 20 years of biopharmaceutical experience building commercial organizations and successfully commercializing novel products, including BTK inhibitor…

11 months ago